Febrile Neutropenia
Symptoms, Doctors, Treatments, Advances & More

Febrile Neutropenia Overview

Save information for later
Sign Up

Learn About Febrile Neutropenia

What is the definition of Febrile Neutropenia?
Febrile neutropenia, also called neutropenic fever, is a condition in which an individual has a fever greater than or equal to 101° F for at least an hour and a low neutrophil count. This is usually due to an infection. Febrile neutropenia commonly occurs as a complication in patients with cancer who are undergoing chemotherapy.
What are the symptoms of Febrile Neutropenia?
Symptoms of febrile neutropenia include a fever greater than or equal to 101° F for at least an hour, a low neutrophil count, and signs and symptoms of an infection such as tenderness or pain.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Febrile Neutropenia?
Treatment for patients with febrile neutropenia depends on their overall condition. Treatments for febrile neutropenia include medications such as fluoroquinolone plus amoxicillin/clavulanate, clindamycin, cefepime, carbapenems, piperacillin, tazobactam, vancomycin, linezolid, daptomycin, polymyxin, colistin, tigecycline, triazole, trimethoprim-sulfamethoxazole, or a nucleoside reverse transcription inhibitor.
Who are the top Febrile Neutropenia Local Doctors?
Elite in Febrile Neutropenia
Elite in Febrile Neutropenia
Referral may be required

Fred Hutchinson Cancer Center

1100 Fairview Ave N, 
Seattle, WA 
206-667-6670
Languages Spoken:
English
See accepted insurances

Gary Lyman is a Hematologist practicing medicine in Seattle, Washington. Dr. Lyman is rated as an Elite provider by MediFind in the treatment of Febrile Neutropenia. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Febrile Neutropenia, Agranulocytosis, Venous Thromboembolism (VTE), and Deep Vein Thrombosis.

Elite in Febrile Neutropenia
Elite in Febrile Neutropenia
Referral may be required
Genolier, VD, CH 

Matti Aapro practices practicing medicine in Genolier, Switzerland. Aapro is rated as an Elite expert by MediFind in the treatment of Febrile Neutropenia. They are also highly rated in 7 other conditions, according to our data. Their clinical expertise encompasses Febrile Neutropenia, Agranulocytosis, HER2 Negative Breast Cancer, and Breast Cancer.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Febrile Neutropenia
Elite in Febrile Neutropenia
Referral may be required
Ankara, TR 

Murat Akova practices practicing medicine in Ankara, Turkey. Mr. Akova is rated as an Elite expert by MediFind in the treatment of Febrile Neutropenia. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Febrile Neutropenia, Agranulocytosis, Sepsis, Urinary Tract Infection (UTI), and Bone Marrow Transplant.

View All Doctors
What are the latest Febrile Neutropenia Clinical Trials?
Comparative Effect of Proton Pump Inhibitors and Gastric Mucosal Protective Agents on Acute Graft-versus-Host Disease Post-Transplantation: A Prospective Randomized Controlled Trial
Comparative Effect of Proton Pump Inhibitors and Gastric Mucosal Protective Agents on Acute Graft-versus-Host Disease Post-Transplantation: A Prospective Randomized Controlled Trial
Enrollment Status: Recruiting
Publish Date: August 28, 2026
Intervention Type: Drug
Study Phase: Not Applicable

Summary: The goal of this clinical trial is to observe whether different gastric protection strategies affect the incidence of acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Proton pump inhibitors (PPIs) are routinely used for gastric protection during transplantation, but their prolonged use may suppress gastric acid, alter gu...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Multicenter, Open-label Phase II Clinical Study Evaluating the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Albipagrastim Alfa for Injection (QLC2519) in Pediatric Solid Tumor Participants
A Multicenter, Open-label Phase II Clinical Study Evaluating the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Albipagrastim Alfa for Injection (QLC2519) in Pediatric Solid Tumor Participants
Enrollment Status: Recruiting
Publish Date: July 24, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: QLC2519 (Mai Li Sheng®) is a new protein drug created by fusing the N-terminal of highly active modified G-CSF with the C-terminal of HSA. The modified G-CSF retained high activity while reducing affinity for the G-CSF receptor, which can significantly inhibit the the G-CSF receptor-mediated (RMC) pathway. The aim of this study is to evaluate the PK/PD characteristics of QLC2519 in preventing chem...

View All Clinical Trials